Trial Talk

Clinical trial results usually tell us how effective a treatment was on average for the overall group of participants, but a key question for clinicians, patients and policy makers is: which individual patients benefit most from the treatment and which don’t benefit as much? In the latest episode of the Trial Talk podcast, Peter Godolphin and David Fisher discuss a new method for determining how treatment effects differ between subgroups of patients across multiple clinical trials, as well as how other meta-analysis researchers can use it.

Resources:

• Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework onlinelibrary.wiley.com/doi/10.1002/jrsm.1590
• Cochrane webinar recording training.cochrane.org/resource/estim…-meta-analysis
• GitHub page for metafloat package in Stata github.com/UCL/metafloat
• WHO REACT Group: IL6 Prospective meta-analysis jamanetwork.com/journals/jama/fullarticle/2781880
• STOPCAP collaborators: Docetaxel IPD meta-analysis www.thelancet.com/journals/lanonc/…00230-9/fulltext

For questions about the within-trial framework for subgroup analysis, you can email d.fisher@ucl.ac.uk or p.godolphin@ucl.ac.uk.
For more information and to access the transcript: bit.ly/43boETF
For questions or feedback on the podcast series, message us at mrcctu.engage@ucl.ac.uk 
As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

 Date of episode recording: 2024-03-12T00:00:00Z
 Duration: 00:28:44
 Language of episode: English
 Presenter: Charlotte Hartley
 Guests: Peter Godolphin, David Fisher
 Producer: Charlotte Hartley
 

What is Trial Talk?

The Trial Talk Podcast explores how our work at the MRC Clinical Trials Unit at UCL is improving health in the UK and worldwide. In this new series, we will hear from world-leading experts about the studies we carry out. We will get inside trials on cancer, infections, and neurodegenerative diseases, explore how public and patient involvement is shaping our studies, and discover new ways to run smarter studies.